Overview
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID). NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of phenylbutazone, mefenamic acid, and indomethacin. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with misoprostol to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).
Indication
Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with misoprostol as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.
Associated Conditions
- Actinic Keratosis (AK)
- Acute Arthritis
- Acute Gouty Arthritis
- Acute Migraine
- Acute Musculoskeletal Pain
- Ankylosing Spondylitis (AS)
- Common Cold
- Fever
- Gout
- Inflammation
- Inflammatory Disease of the Oral Cavity
- Inflammatory Disease of the throat
- Inflammatory Reaction of the Nerve
- Joint Pain
- Juvenile Idiopathic Arthritis (JIA)
- Menstrual Distress (Dysmenorrhea)
- Muscle Inflammation
- Myalgia
- Neuropathic Pain
- Ocular Inflammation
- Osteoarthritis (OA)
- Osteoarthritis of the Knee
- Pain
- Pain caused by Rheumatism
- Pericarditis
- Photophobia
- Postoperative Inflammatory Response
- Postoperative pain
- Primary Dysmenorrhoea
- Radicular Pain
- Rheumatism
- Rheumatoid Arthritis
- Seasonal Allergic Conjunctivitis
- Spinal pain
- Tendon pain
- Vertebral column pain
- Acute Musculoskeletal injury
- Acute, moderate, severe Pain, Inflammatory
- Localized soft tissue rheumatism
- Mild to moderate joint pain
- Mild to moderate pain
- Minor pain
- Perioperative miosis
Research Report
Diclofenac: A Comprehensive Pharmacological and Clinical Review
1. Introduction to Diclofenac
1.1. Overview and Summary
Diclofenac is a well-established phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It is primarily utilized for the management of signs and symptoms associated with various arthritic conditions, including osteoarthritis and rheumatoid arthritis.[1] Its therapeutic applications extend to ankylosing spondylitis and a range of other painful states, such as menstrual cramps (primary dysmenorrhea) and acute migraine attacks.[2] The pharmacological profile of diclofenac is characterized by its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.[3]
The broad spectrum of indications for diclofenac underscores its efficacy in conditions where prostaglandins play a significant pathogenic role. Prostaglandins are key mediators in inflammation, pain sensitization, and fever development. By inhibiting their synthesis, diclofenac offers relief across a diverse array of clinical scenarios. Its utility in both chronic inflammatory diseases like arthritis and acute painful conditions such as migraines highlights its versatility as a therapeutic agent.[1] This versatility is a direct consequence of its fundamental mechanism of action as an NSAID, which targets the cyclooxygenase (COX) enzymes responsible for prostaglandin production. However, this same mechanism also underpins its potential for adverse effects, particularly concerning the gastrointestinal and cardiovascular systems, which are significant enough to warrant boxed warnings from regulatory authorities like the U.S. Food and Drug Administration (FDA).[3] The widespread and long-standing use of diclofenac implies a considerable clinical impact in pain and inflammation management. Concurrently, this extensive use necessitates a comprehensive understanding and careful consideration of its
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/08/20 | Not Applicable | Recruiting | |||
2025/08/03 | Not Applicable | Not yet recruiting | Mariam Hesham Mahmoud Abdelfattah Eissa | ||
2025/07/28 | Not Applicable | Completed | |||
2025/07/17 | Not Applicable | Recruiting | |||
2025/07/17 | Not Applicable | Recruiting | Air Force Military Medical University, China | ||
2025/05/25 | Phase 1 | Not yet recruiting | Synartro AB | ||
2025/04/22 | Not Applicable | Recruiting | |||
2025/04/09 | Phase 4 | Active, not recruiting | Haydarpasa Numune Training and Research Hospital | ||
2025/04/01 | Not Applicable | Recruiting | The Second Affiliated Hospital of Hainan Medical University | ||
2025/02/25 | Not Applicable | Completed | Assumpta Nnenna Nweke |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
A-S Medication Solutions | 50090-4018 | TOPICAL | 16.05 mg in 1 mL | 9/17/2018 | |
Proficient Rx LP | 71205-618 | TOPICAL | 10 mg in 1 g | 5/2/2022 | |
medsource pharmaceuticals | 45865-964 | TOPICAL | 16.05 mg in 1 mL | 12/30/2019 | |
Bryant Ranch Prepack | 71335-9720 | ORAL | 50 mg in 1 1 | 12/8/2022 | |
A-S Medication Solutions | 50090-4621 | TOPICAL | 10 mg in 1 g | 2/5/2021 | |
Rebel Distributors Corp | 21695-791 | TOPICAL | 10 mg in 1 g | 12/18/2008 | |
Bryant Ranch Prepack | 71335-0371 | TOPICAL | 10 mg in 1 g | 9/17/2018 | |
Asclemed USA, Inc. | 76420-012 | TOPICAL | 16.05 mg in 1 mL | 10/12/2022 | |
Preferred Pharmaceuticals Inc. | 68788-9435 | TOPICAL | 30 mg in 1 g | 6/12/2023 | |
Preferred Pharmaceuticals Inc. | 68788-7103 | ORAL | 75 mg in 1 1 | 5/4/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
REMETHAN GEL 1% | SIN08561P | GEL | 10 mg/g | 2/5/1996 | |
VOREN SUPPOSITORY 12.5 mg | SIN06614P | SUPPOSITORY | 12.5 mg | 10/12/1991 | |
REMAFEN TABLET 25 mg | SIN05990P | ENTERIC COATED TABLET | 25 mg | 5/27/1991 | |
NEODOL INJECTION 25 mg/ml | SIN09444P | INJECTION | 25 mg/ml | 7/16/1997 | |
DICLOGEL 1% w/w | SIN09170P | GEL | 1% w/w | 1/25/1997 | |
RHEWLIN FORTE TABLETS 50 mg | SIN05560P | ENTERIC COATED TABLET | 50 mg | 3/7/1991 | |
VOLTAREN 25 SUPPOSITORY 25 mg | SIN05467P | SUPPOSITORY | 25 mg | 2/22/1991 | |
FENAC-50 TABLET 50 mg | SIN09312P | TABLET, FILM COATED | 50 mg | 4/25/1997 | |
SALONPAS DICLOFENAC GEL 1% | SIN16418P | GEL | 1g/100g | 1/17/2022 | |
ULTRAFEN 50 SUPPOSITORY 50 mg | SIN10519P | SUPPOSITORY | 50 mg | 12/8/1998 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
GASICA 25 ENTERIC COATED TABLETS 25MG | N/A | N/A | N/A | 2/1/2019 | |
VOLTAREN ENTERIC COATED TAB 50MG (TURKEY) | N/A | N/A | N/A | 11/20/2012 | |
FUNGOLING EMULSIFIED GEL 1%W/V | N/A | N/A | N/A | 7/15/2006 | |
DICLOFENAC E.C. TAB 50MG | N/A | N/A | N/A | 4/1/2005 | |
DICLOFENAC 100 STADA RETARD TAB 100MG | N/A | N/A | N/A | 11/11/1994 | |
LESFLAM 25 TAB 25MG | N/A | N/A | N/A | 1/14/2006 | |
VARTELON GEL 1%W/W | N/A | N/A | N/A | 8/8/2001 | |
METATUHON TABLETS 25MG | N/A | N/A | N/A | 1/23/2025 | |
STADLOFEN 50 GASTRO-RESISTANT TABLETS 50MG | N/A | N/A | N/A | 6/13/2022 | |
OLFEN-50 LACTAB 50MG | N/A | N/A | N/A | 1/20/1988 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
VOLTAREN RAPID EXTRA STRENGTH diclofenac potassium 25 mg tablet blister pack | 42942 | Medicine | A | 5/27/1993 | |
VICLOFEN TABLETS diclofenac sodium 25 mg tablet blister pack | 75245 | Medicine | A | 7/20/2000 | |
SANDOZ DICLOFENAC GEL diclofenac sodium 10 mg/g gel tube | 69604 | Medicine | A | 6/17/1999 | |
AMCAL DICLOFENAC ANTI-INFLAMMATORY diclofenac sodium 25 mg enteric coated tablet blister pack | 290716 | Medicine | A | 6/27/2017 | |
VOLTAREN diclofenac sodium 50mg suppository | 96811 | Medicine | A | 5/25/2004 | |
VOLTAREN 25 diclofenac disodium 25mg tablet blister pack | 166496 | Medicine | A | 12/17/2009 | |
DICLOFENAC 25 diclofenac potassium 25 mg soft capsule blister pack | 284365 | Medicine | A | 1/9/2017 | |
INFLAMAX SPRAY diclofenac sodium 4% w/w bottle | 209248 | Medicine | A | 5/7/2013 | |
PRICELINE ANTI-INFLAMMATORY PAIN RELIEF GEL diclofenac sodium 10mg/g tube | 127744 | Medicine | A | 5/11/2006 | |
CAMBIA diclofenac potassium 50 mg powder for oral liquid sachet | 123192 | Medicine | A | 5/10/2007 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
SANDOZ DICLOFENAC MISOPROSTOL | 02400596 | Tablet - Oral | 50 MG | N/A | |
DICLOFENAC EC | sanis health inc | 02352397 | Tablet (Enteric-Coated) - Oral | 50 MG | 6/15/2010 |
PENTA-DICLOFENAC - 50MG | pentapharm ltd. | 02229592 | Tablet (Enteric-Coated) - Oral | 50 MG | 6/6/1997 |
VOLTAREN SR | novartis pharmaceuticals canada inc | 00782459 | Tablet (Extended-Release) - Oral | 75 MG | 12/31/1989 |
VOLTAREN | novartis pharmaceuticals canada inc | 00632732 | Suppository - Rectal | 100 MG | 12/31/1985 |
SANDOZ-DICLOFENAC | 02261960 | Tablet (Delayed-Release) - Oral | 50 MG | 2/2/2006 | |
RHO-DICLOFENAC | rhoxalpharma inc | 02236725 | Tablet (Enteric-Coated) - Oral | 50 MG | N/A |
PMS-DICLOFENAC-MISOPROSTOL | 02413469 | Tablet (Delayed-Release) - Oral | 50 MG | 12/11/2018 | |
PMS-DICLOFENAC | 02231502 | Tablet (Enteric-Coated) - Oral | 25 MG | 11/28/1997 | |
NTP-DICLOFENAC POTASSIUM | teva canada limited | 02346281 | Tablet - Oral | 50 MG | N/A |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
DOLO-VOLTAREN 46,5 MG COMPRIMIDOS DISPERSABLES | Novartis Farmaceutica S.A. | 61440 | COMPRIMIDO DISPERSABLE | Medicamento Sujeto A Prescripción Médica | Commercialized |
DOLOTREN 46,5 mg comprimidos dispersables | 60068 | COMPRIMIDO DISPERSABLE | Medicamento Sujeto A Prescripción Médica | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.